BHC - Bausch Health to acquire liver drug developer Durect for $1.75 per share
2025-07-29 08:35:55 ET
More on Bausch Health Companies, DURECT
- Bausch Health: Repricing Potential Driven By Deleveraging
- Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
- Bausch Health Companies Inc. 2025 Q1 - Results - Earnings Call Presentation
- Bausch Health to redeem ~$602M of outstanding notes due 2026
- Insider trades: Broadcom, Dell among notable names this week